EGFR and lung adenocarcinoma: The results were in good agreement with our previous study, in which local recurrence was 10.8% and 22% in EGFR-mutant and wild-type lung adenocarcinoma, respectively.10 Comparably, Mak et al.20 retrospectively examined locally advanced lung adenocarcinoma patients treated by chest radiotherapy.